Humacyte (NASDAQ:HUMA) Receives “Buy” Rating from D. Boral Capital

D. Boral Capital reaffirmed their buy rating on shares of Humacyte (NASDAQ:HUMA) in a report issued on Wednesday,Benzinga reports. The firm currently has a $25.00 target price on the stock.

Several other research firms also recently weighed in on HUMA. Benchmark raised their target price on shares of Humacyte from $15.00 to $17.00 and gave the company a “buy” rating in a report on Monday, December 23rd. HC Wainwright reaffirmed a “buy” rating and set a $15.00 price target (up from $12.00) on shares of Humacyte in a report on Friday, December 20th. One analyst has rated the stock with a hold rating, six have given a buy rating and one has assigned a strong buy rating to the stock. Based on data from MarketBeat.com, the stock presently has an average rating of “Buy” and a consensus price target of $13.71.

Humacyte Stock Performance

HUMA stock opened at $3.43 on Wednesday. Humacyte has a one year low of $2.81 and a one year high of $9.97. The company has a fifty day moving average of $4.38 and a 200-day moving average of $4.99. The stock has a market capitalization of $431.70 million, a PE ratio of -2.56 and a beta of 1.30.

Institutional Trading of Humacyte

A number of institutional investors have recently bought and sold shares of the company. Vontobel Holding Ltd. bought a new stake in Humacyte in the fourth quarter worth approximately $50,000. Petros Family Wealth LLC acquired a new position in Humacyte in the fourth quarter valued at about $50,000. Syon Capital LLC acquired a new stake in Humacyte in the 4th quarter valued at about $54,000. Brookstone Capital Management acquired a new position in Humacyte in the fourth quarter valued at approximately $56,000. Finally, ACT Wealth Management LLC bought a new position in Humacyte during the 4th quarter worth approximately $57,000. Institutional investors and hedge funds own 44.71% of the company’s stock.

Humacyte Company Profile

Humacyte, Inc engages in the development and manufacture of off-the-shelf, implantable, and bioengineered human tissues for the treatment of diseases and conditions across a range of anatomic locations in multiple therapeutic areas. The company using its proprietary and scientific technology platform to engineer and manufacture human acellular vessels (HAVs) to be implanted into patient without inducing a foreign body response or leading to immune rejection.